5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-

Request For Quotation
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- Basic information
Product Name:5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-
Synonyms:5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-
CAS:1022094-34-3
MF:C46H56N6O16
MW:948.97
EINECS:
Product Categories:
Mol File:1022094-34-3.mol
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- Structure
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- Chemical Properties
Boiling point 1198.9±65.0 °C(Predicted)
density 1.50±0.1 g/cm3(Predicted)
pka7.35±0.60(Predicted)
form Solid
color Orange to red
Safety Information
MSDS Information
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- Usage And Synthesis
UsesVal-Cit-PABC-DOX (compound 10109), an epsilon-poly-L-lysine-based drug conjugate, is an agent-linker conjugate for ADC by using a DNA topoisomerase I and topoisomerase II inhibitor, Doxorubicin (HY-15142), linked via the linker, Val-Cit-PABC[1].
IC 50Traditional Cytotoxic Agents
References[1] Furao Zhang, et al. Epsilon-poly-l-lysine-based drug conjugate, intermediate thereof, and application thereof. WO2023078464A1.
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- Preparation Products And Raw materials
Tag:5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)-(1022094-34-3) Related Product Information
DBCO-PEG4-VC-pAb-dmea-PNU-159682 Azide-PEG8-Val-Cit-Doxorubicin Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 PNU-EDA-Gly5 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- vc-PAB-DMEA-PNU159682